MELBOURNE: 4DMedical Limited said Monday it has signed a binding agreement to acquire contextflow GmbH, an Austrian medical technology company, in a deal that gives the Australian lung-imaging firm an immediate commercial and clinical presence across Europe.
The acquisition positions 4DMedical across three continents, adding Europe to its existing operations in North America and the ANZ region. Financial terms include an upfront payment of approximately 11.42 million euros (A$18.56 million) in cash plus 56,235 ordinary shares. An additional earnout of up to 2.59 million zero-exercise-price options may be paid over two years if performance milestones are met.
4DMedical said it acquired contextflow on “heavily discounted terms” and will retain about 19.0 million euros (A$30.8 million) in accumulated tax losses from the Austrian business, which it said enhanced the overall economic value of the transaction.
The deal provides immediate access to Europe’s respiratory and thoracic imaging market, estimated at $1.5 billion to $2 billion USD, without the time and cost of building a new operation from the ground up. Contextflow, based in Vienna, specializes in lung cancer screening and AI-driven thoracic imaging. Its product suite carries the CE mark under the European Medical Device Regulation and has secured insurance reimbursement contracts in Germany.
“We have grown our market opportunity by 50% for only 6.5% of our existing cash balance, and with less than half a percent of dilution to shareholders,” said Andreas Fouras, CEO and founder of 4DMedical.
Markus Holzer, CEO of contextflow, will become general manager of Europe for 4DMedical. The transaction is expected to close around late July 2026, subject to approval from the Austrian Federal Ministry of Economy, Energy and Tourism and other customary conditions. Shareholder approval will also be sought for the contingent earnout options.
4DMedical’s shares trade on the Australian Securities Exchange under the symbol 4DX.
